Amaroq Therapeutics
6 employees on LinkedIn · 3 known investors
Amaroq Therapeutics develops first-in-class therapies targeting long non-coding RNAs (lncRNAs) implicated in oncology and other diseases. The company uses proprietary platforms to discover, validate, and create precision medicines against disease-relevant lncRNAs, focusing initially on oncology programs with high unmet medical need.
Investors · 3
Frequently asked questions
- What does Amaroq Therapeutics do?
- Amaroq Therapeutics develops first-in-class therapies targeting long non-coding RNAs (lncRNAs) implicated in oncology and other diseases. The company uses proprietary platforms to discover, validate, and create precision medicines against disease-relevant lncRNAs, focusing initially on oncology programs with high unmet medical need.
- Who are Amaroq Therapeutics's investors?
- Amaroq Therapeutics's investors include Booster Innovation Fund, Cure Kids Ventures, Tenmile.